Released Feb 7, 2019, after the close
10-K filed Mar 18, 2019, 77 days after period end · 0001162194-19-000020
Q4 2018 · 10-K
Revenue$32.33M$32.33M +16.5% vs Q4 2017+11.6% vs Q3 2018
Net Income-$14.78M-$14.78M derivedN/M vs Q4 2017N/M vs Q3 2018
EPS Diluted-$0.36-$0.36 N/M vs Q4 2017N/M vs Q3 2018
Gross Profitderived$18,811,000—
Operating Incomederived-$11,118,000N/M
Operating Cash Flowderived-$638,000N/M
Free Cash Flowderived-$658,000N/M
Margins · derived
Gross margin58.2%
Operating margin-34.4%−2.9 pt vs Q4 2017
Net margin-45.7%−8.0 pt vs Q4 2017
What the release said
The release
Same quarter
| Metric | Q4 2018 | Q4 2017 | Q4 2016 | Q4 2015 |
|---|---|---|---|---|
| Revenue | $32.33M | $27.75M | $25.08M | $30.72M |
| Net Income | -$14.78M | -$10.46M | -$17.70M | -$12.88M |
| EPS Diluted | -$0.36 | -$0.27 | -$0.61 | -$0.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR